I also choose to see this a positive sign for U.S. pipeline indications.
Although I would've liked to see a higher strike price for the options, highly qualified and experienced talent doesn't come cheap (especially in the U.S.). These options will dilute existing shareholders by around 1.5% (I think) but they should still provide Ravi with sufficient incentive to progress the company/share price.
I can only assume that management see their investment in Ravi as beneficial to the future of the company and its shareholders. I'll give them some time to prove their investment in Ravi.
Just the thoughts of another naïve retail investor.
Below are the thoughts of someone who knows more:
Ann: Orthocell Appoints Non-Executive Director Dr Ravi Thadhani, page-32
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $148.2M | |||
| Open | High | Low | Value | Volume |
| 62.5¢ | 62.5¢ | 61.0¢ | $801.4K | 1.299M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 61.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.0¢ | 27038 | 3 |
View Market Depth
| Last trade - 12.49pm 01/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |